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to begin with and be bloody-minded 
about continuing this specific interest. 
You should always enjoy biology, even 
when some aspects of doing research 
are tedious or even unsuccessful. If 
you don’t enjoy what you are doing, 
then you might as well be in business 
and be paid well to do boring things! 
Beyond that it is a matter of personal 
style; my advice depends upon where 
you are on the personality gradient 
between risk-adverse and risk-prone, 
and how comfortable you are with the 
unpredictable. 
At one extreme, if you are (like 
me) more risk-prone, you should be 
extremely exploratory, daring, and 
original in the scientific questions 
you ask and do research on. Do 
‘interesting’ science rather than 
‘important’ science. This is more likely 
to yield significant new discoveries 
because few people have addressed 
supposedly ‘unimportant’ questions. 
The history of science suggests 
that almost no major discoveries 
were done because that research 
topic was ‘important’ at that time. 
There is a bigger risk to your career 
in going for interesting science for 
three reasons: you might get into 
an intellectual cul-de-sac, so you 
need to learn how to recognize dead 
ends; it is much harder to get funding 
for really original or ‘unimportant’ 
science; you need to have thorough 
knowledge which cuts across several 
scientific fields, which takes longer 
and requires more effort.  You will 
also have to learn how to recognize 
completely new phenomena.  Don’t 
get caught in intellectual ruts caused 
by excessive reading of the literature, 
but do be careful to ensure that you 
give all credit to all published work.  
Let natural phenomena be your guide 
rather than the literature if you want to 
make really new discoveries.
At the other extreme, if you are 
risk-adverse, then stick to ‘important’ 
and applied science or technology, 
it is far easier because questions 
are well-defined and funding is easy, 
and its easy to churn out papers 
making tiny advances, so your career 
will advance quickly. But the risk is 
that you won’t make any significant 
contribution to science and your name 
will be forgotten after you go into 
administration because tiny advances 
are not satisfying, or retire, rich. As you 
can see, where you sit on the gradient 
is a matter of taste and style, but don’t 
forget your original goals!
What do you think of the worldwide 
trend in research councils and 
foundations towards more and more 
applied research at the expense 
of ‘pure’ research? I am worried by 
this trend. It is presumably driven by 
the fact that research councils and 
foundations have to justify spending 
money to their governments and 
boards, and it is difficult to sustain 
funding if it seems ‘unimportant’ 
or even ‘useless’. Very few people 
controlling research funding realize 
that breakthroughs in science are like 
a tree giving off thousands of seeds of 
which only a few germinate. As a result, 
the people in councils have to favor 
‘important’ science, and researchers 
have to stretch descriptions of basic 
research to sound as though it has 
significant applied implications. 
This is terrible, for two reasons. First 
it inhibits genuine exploratory (‘blue 
sky’) research, hence greatly reduces 
the probability of genuinely new 
discoveries and concepts. Second, 
and positively dangerous, the constant 
exaggerated description of all research 
projects having supposedly significant 
applied outcomes is constantly raising 
the expectations of the public. As this 
gets worse and worse expectations 
rise and failures become more 
frequent, and public confidence in 
science declines. This is the classical 
problem of short-term gains at 
the expense of long-term survival. 
Pretending all science has immediate 
beneficial applications results in long 
term destruction of support for and 
interest in science. Right now we are 
just depending upon sheer numbers 
of researchers stumbling on new 
phenomena in a social atmosphere of 
rapidly declining confidence in science 
because we are constantly raising 
expectations. Somebody needs to write 
a popular book about the cultural/social 
environment that has favored major 
scientific breakthroughs in the past, 
and how this needs to be encouraged. 
We risk the long-term survival of 
science by not letting the public know 
how science really proceeds.
If you were to start over, would you 
do it again? Yes! I really enjoy doing 
science, satisfying my curiosity and 
discovering the unexpected.
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Quick guidesWhat is oncogene addiction? The term 
‘oncogene addiction’ was first coined 
by Bernard Weinstein to describe 
the dependency of certain tumor 
cells on a single activated oncogenic 
protein or pathway to maintain their 
malignant properties, despite the 
likely accumulation of multiple gain- 
and loss-of-function mutations that 
contribute to tumorigenicity. The 
term has been reinforced by several 
reported findings in animal tumor 
models in which oncogene-driven 
tumors, either generated as xenografts 
or through the use of genetically 
engineered models, have been found 
to undergo regression, associated with 
proliferative arrest, apoptosis, and/or 
differentiation following the acute 
inhibition of oncoprotein function.
Should this surprise anyone? Many 
scientists in the oncology research 
community view the oncogene 
addiction concept as ‘trivial’, 
suggesting that it is obvious that a 
mutation that contributes causally 
to tumorigenesis would be required 
for cancer cells to maintain their 
malignant phenotype. However, this 
is almost certainly not universally 
true. Thus, cancer cells frequently 
undergo genome instability caused 
by disruption of normal DNA repair 
and replication mechanisms, and this 
can certainly result from mutational 
events that affect, for example, 
genes encoding components of the 
DNA damage response machinery. 
Such mutational events lead to the 
accumulation of additional potentially 
oncogenic mutations, but are clearly 
exerting their actions via a ‘hit and 
run’ mechanism. Similarly, one could 
imagine oncogenic events that play a 
role in the initiation of tumorigenesis, 
for example, by expanding a tumor 
stem cell population, but that are 
not necessarily required to maintain 
tumorigenicity once a tumor has 
sufficiently ‘matured’. 
What is the ‘oncogenic shock’ theory? 
Oncogenic shock is a signaling 
mechanism that has been proposed 
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addicted cancer cells upon inhibition 
of the oncoprotein to which they are 
addicted. Based on studies with cell 
line culture models, oncogenic shock 
refers to an acute imbalance in the 
output of pro-apoptotic and pro-
survival signaling from an oncogenic 
kinase (such as EGFR or BCR–ABL) 
following kinase inhibition by drug 
exposure. Such kinases are believed to 
transduce both short-lived pro-survival 
signals that are rapidly attenuated 
upon kinase inhibition, and longer-lived 
pro-apoptotic mechanisms that decay 
more slowly following kinase inhibition. 
In the absence of drug treatment, 
the pro-apoptotic signals are held 
in check by pro-survival signals, 
thereby promoting cancer cell survival. 
However, upon drug-mediated kinase 
inhibition, the differential decay rate 
of these two types of signals reverses 
the balance, leading to excessive pro-
apoptotic signaling and consequent 
tumor cell death. While this is difficult 
to demonstrate in a clinical context, 
recent studies in mouse tumor models 
have yielded findings that support the 
oncogenic shock mechanism in vivo.
Is oncogene addiction clinically 
significant? The phenomenon of 
oncogene addiction, irrespective of its 
mechanistic underpinnings, is widely 
recognized as a likely contributor 
to the impressive clinical activity 
that has recently been observed 
following treatment with so-called 
‘rationally-targeted’ agents. The 
clinical responses to such single 
agents in patients with metastatic 
disease that was largely refractory to 
standard chemotherapies is nothing 
short of remarkable. For example, 
a high percentage of EGFR mutant 
non-small cell lung cancers, BRAF 
mutant melanomas, and ALK mutated 
lung tumors respond to drugs that 
selectively inhibit these mutationally 
activated kinases. Similar clinical 
observations in BCR–ABL translocated 
cases of chronic myelogenous 
leukemia, PDGF receptor and  
c-KIT mutant gastrointestinal tumors, 
and JAK-mutant myeloproliferative 
disorders provide additional examples 
of genotype-associated drug 
responses seemingly associated 
with oncogene addiction. Such 
findings have prompted great interest 
in exploring additional clinical 
opportunities in which oncogene 
addiction provides a rationale for matching patients with the most 
effective drug therapies. Additional 
examples of mutationally activated 
targets that are currently being 
examined in this regard are PI-3 kinase, 
AKT, MEK, FGF receptor, and MET. 
Such mutationally activated oncogenes 
have been referred to as the ‘Achilles’ 
heels’ of cancer.
Is this only relevant for kinases? The 
most clinically validated examples 
of oncogene addiction have been 
associated with mutationally 
activated kinases. However, cell 
culture and animal tumor studies 
have demonstrated a likely role for 
oncogene addiction for other important 
cancer genes, such as c-MYC and 
RAS. Indeed, the first experimental 
demonstrations of oncogene addiction 
were in the setting of MYC- or RAS-
driven mouse tumors, in which acute 
inhibition of expression of these 
inducible oncogenes led to rapid 
tumor regression. Thus, it is possible 
that a variety of oncogenes, beyond 
the activated kinases, are associated 
with oncogene addiction. However, the 
development of drugs that inhibit the 
function of such proteins (such as MYC 
and RAS) can be substantially more 
challenging than it has been for the 
kinases.
How about non-oncogene addiction? 
The term ‘non-oncogene addiction’ 
was first coined by Steve Elledge 
in the context of findings by Susan 
Lindquist’s group that revealed a 
requirement for heat-shock factor 
1 (HSF1) to maintain malignancy in 
tumor cells experiencing various forms 
of stress. HSF1 is not mutated in 
cancer, but its requirement in cancer 
cells is apparently revealed in specific 
physiological contexts associated with 
tumors, such as hypoxia. If HSF1 was 
found to be a tractable drug target, 
such findings could pave the way to 
a drug-targeting strategy associated 
with non-oncogene addiction. Other 
examples of non-oncogene addiction 
are beginning to accumulate in the 
published literature.
Is non-oncogene addiction clinically 
relevant? One of the best examples 
of non-oncogene addiction relates 
to the so-called ‘synthetic lethality’ 
associated with drugs that inhibit 
poly(ADP ribose) polymerase (PARP). 
Although PARP is not mutationally 
activated in cancer, PARP inhibition appears to be selectively effective 
in tumors harboring loss-of-function 
alleles of the tumor suppressors 
BRCA1 and BRCA2. In those contexts, 
cancer cells suffering a deficiency 
in DNA repair as a consequence 
of losing BRCA function become 
vulnerable to PARP inhibition, which 
further contributes to DNA damage 
that cannot be repaired in ‘BRCA-less’ 
tumors, leading to tumor cell death.
And what about ‘lineage addiction’? 
Lineage addiction refers to yet another 
form of non-oncogene addiction in 
which cell-lineage-specific factors 
may be required to maintain tumor 
cell identity and possibly function, 
thereby defining a potential therapeutic 
targeting strategy. Among the best 
examples defined thus far is the 
demonstration that some melanomas 
remain dependent for their survival 
on the maintenance of elevated 
expression of the micropthalmia-
associated transcription factor (MITF) — 
which does not undergo mutation in 
melanomas.
How will we find more examples 
of oncogene and non-oncogene 
addiction? Now that we have proof-
of-concept that targeting oncogene 
addiction states can yield clinical 
efficacy, there has been a substantial 
increase in the effort to find additional 
examples. Much of this analysis 
has been in the form of RNAi-based 
screens, owing to the power of this 
technology to functionally interrogate 
the human genome in the context of 
cell-based assays. Consequently, we 
are beginning to see the emergence 
of a large number of candidate 
therapeutic targets that will require 
further validation to be considered 
viable for drug discovery.
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